RxDoctor Payments Data

Leon Kupferwasser, MD

Cardiovascular Disease · van Nuys, CANPI 1316067457

Payments from drug & device makers

$6,515in general payments, 2019–2025

Across 328 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$897
  • Merck$789
  • Novartis$715
  • Amgen$490
  • AstraZeneca$348
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$313
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,45099%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,515 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,146,767
Medicare patients
1,865
Services billed
16,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban589$689,276
EntrestoSacubitril/Valsartan152$201,839
XareltoRivaroxaban134$136,401
FarxigaDapagliflozin Propanediol106$112,553
Repatha SureclickEvolocumab76$69,828
VerquvoVericiguat27$21,729
JardianceEmpagliflozin26$20,876
BrilintaTicagrelor22$20,534
DapagliflozinDapagliflozin Propanediol23$15,079
CorlanorIvabradine Hcl15$14,918
Repatha SyringeEvolocumab17$13,013
Nebivolol Hcl220$11,283
Metoprolol Succinate534$7,000
Atorvastatin Calcium622$5,620
Hydralazine Hcl421$5,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$897$689,276589 claims
NovartisEntresto$715$201,839152 claims
Johnson & JohnsonXarelto$258$136,401134 claims
AstraZenecaFarxiga, Brilinta$348$133,087128 claims
MerckVerquvo$789$21,72927 claims
Boehringer IngelheimJardiance$251$20,87626 claims
AmgenCorlanor$490$14,91815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →